| dc.contributor.author | López‐Siguero, Juan P. | |
| dc.contributor.author | Martínez‐Aedo, Maria J. | |
| dc.contributor.author | Bermúdez de la Vega, José Antonio | |
| dc.contributor.author | Bosch‐Muñoz, Jordi | |
| dc.contributor.author | Lechuga Sancho, Alfonso María | |
| dc.contributor.author | Villalobos, Triana | |
| dc.contributor.author | SGA Study Investigator Collaborative Group | |
| dc.contributor.other | Materno-Infantil y Radiología | es_ES |
| dc.date.accessioned | 2022-02-15T08:16:11Z | |
| dc.date.available | 2022-02-15T08:16:11Z | |
| dc.date.issued | 2021-12 | |
| dc.identifier.issn | 0300-0664 | |
| dc.identifier.issn | 1365-2265 (internet) | |
| dc.identifier.uri | http://hdl.handle.net/10498/26261 | |
| dc.description.abstract | Objective In children born small for gestational age (SGA), the relationship between growth hormone (GH) treatment and insulin resistance (IR) has only been investigated for a short period, necessitating a longer observation period. This study aimed to evaluate the long-term (10 years) effect of GH to SGA-children on IR and safety during treatment. Design This was a multicenter observational study. Patients: SGA-children who received GH treatment in Spain (stratified by Tanner-stage and age at GH onset [two groups: <= 6 years old or >6 years old]). Measurements: The analysed variables (yearly measures) included auxologic, metabolic (insulin-like growth factor-1 (IGF-1), height velocity [HV], weight and homeostatic model assessment-IR [HOMA-IR]) and safety data. Data were collected prospectively (since the study approval: 2007) and retrospectively (since the initiation of GH treatment: 2005-2007). Results A total of 389 SGA children (369 Tanner-I) were recruited from 27 centres. The mean age (standard deviation) of the children at GH treatment onset was 7.2 (2.8) years old. IGF-1 (standard deviation score [SDS]) and HOMA-IR values tended to increase until the sixth year of GH-treatment, with significant differences being observed only during the first year, while these remained stable in the later years (within normal ranges). Height (SDS) increased significantly (basal: -3.0; tenth year: -1.13), and the maximum HV (SDS) occurred during the first year (2.75 +/- 2.39). Conclusions HOMA-IR values increased significantly in SGA-children during the first year of GH-treatment, remained stable and were within normal ranges in all cases. Our 10-year data suggests that long-term GH treatment does not promote IR and is well-tolerated, safe and effecti | es_ES |
| dc.format | application/pdf | es_ES |
| dc.language.iso | eng | es_ES |
| dc.publisher | WILEY | es_ES |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.source | Clinical Endocrinology. 2021;1–11 | es_ES |
| dc.subject | efficacy | es_ES |
| dc.subject | growth hormone | es_ES |
| dc.subject | homeostatic model assessment | es_ES |
| dc.subject | insulin resistance | es_ES |
| dc.subject | long‐term follow‐up | es_ES |
| dc.subject | safety | es_ES |
| dc.subject | small for gestational age | es_ES |
| dc.title | Growth hormone treatment does not to lead to insulin resistance nor excessive rise in IGF-1 levels, while improving height in patients small for gestational age A long-term observational study | es_ES |
| dc.type | journal article | es_ES |
| dc.rights.accessRights | open access | es_ES |
| dc.identifier.doi | 10.1111/cen.14626 | |